{
    "clinical_study": {
        "@rank": "122817", 
        "acronym": "SFA ISR", 
        "arm_group": [
            {
                "arm_group_label": "Lutonix DCB", 
                "arm_group_type": "Experimental", 
                "description": "Lutonix Paclitaxel Drug Coated Balloon"
            }, 
            {
                "arm_group_label": "PTA Catheter", 
                "arm_group_type": "Active Comparator", 
                "description": "Standard Uncoated Balloon Angioplasty Catheter"
            }
        ], 
        "brief_summary": {
            "textblock": "To assess the safety and efficacy of the Lutonix Drug Coated Balloon for treatment of\n      femoropopliteal artery (SFA) in-stent restenosis (ISR)."
        }, 
        "brief_title": "Lutonix\u00ae Drug Coated Balloon vs. Standard Balloon Angioplasty for Treatment of Femoropopliteal In-Stent Restenosis", 
        "completion_date": {
            "#text": "March 2019", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Femoral Artery Stenosis", 
            "Femoral Artery Occlusion", 
            "Restenosis"
        ], 
        "condition_browse": {
            "mesh_term": "Arterial Occlusive Diseases"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Key Inclusion Criteria:\n\n          1. Male or non-pregnant female \u226518 years of age\n\n          2. Rutherford Clinical Category 2-4\n\n          3. Significant (\u2265 50%) restenosis of a previous bare (not covered and not drug-eluting)\n             nitinol stent(s) in the femoropopliteal artery\n\n          4. Lesion measures between 4 and 18 cm\n\n          5. Target vessel diameter between \u22654 and \u22646 mm and able to be treated with available\n             device size matrix\n\n          6. A patent inflow artery free from significant lesion (\u226550% stenosis) as confirmed by\n             angiography\n\n          7. Successful crossing and predilatation of the target lesion with a guidewire\n\n          8. At least one patent native outflow artery to the ankle, free from significant (\u226550%)\n             stenosis as confirmed by angiography that has not previously been (nor planned to be)\n             revascularized\n\n          9. No other prior vascular or surgical interventions within 2 weeks before and/or\n             planned 30 days after the protocol treatment\n\n        Key Exclusion Criteria:\n\n          1. Life expectancy of <1 year\n\n          2. Patient is currently participating in an investigational drug or other device study\n             or previously enrolled in this study NOTE: Enrollment in another drug or device\n             clinical trial during the follow up period is not allowed\n\n          3. History of stroke within 3 months\n\n          4. History of MI, thrombolysis or angina within 2 weeks of enrollment\n\n          5. Prior vascular surgery of the index limb, with the exception of remote common femoral\n             patch angioplasty separated by at least 2 cm from the target lesion\n\n          6. Target lesion involves a previously placed covered stent or drug-eluting stent\n\n          7. Grade 4 or 5 stent fracture (mal-aligned components or trans-axial spiral\n             configuration) in the restenotic stent\n\n          8. Inability to take required study medications or allergy to contrast that cannot be\n             adequately managed with pre- and post-procedure medication\n\n          9. Known inadequate distal outflow (>50 % stenosis of distal popliteal and/or all three\n             tibial vessels), or planned future treatment of vascular disease distal to the target\n             lesion\n\n         10. Intended use of adjunctive treatment modalities (i.e. laser, atherectomy, cryoplasty,\n             scoring/cutting balloon, stents, etc.)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "240", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 12, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02063672", 
            "org_study_id": "CL0018-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "Lutonix DCB", 
                "intervention_name": "Lutonix DCB", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "PTA Catheter", 
                "description": "PTA Catheter", 
                "intervention_name": "Standard Uncoated Balloon Angioplasty Catheter", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 28, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "New Haven", 
                        "country": "United States", 
                        "state": "Connecticut", 
                        "zip": "06510"
                    }, 
                    "name": "Yale University"
                }, 
                "investigator": {
                    "last_name": "Carlos Mena, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33140"
                    }, 
                    "name": "Mount Sinai Medical Center"
                }, 
                "investigator": {
                    "last_name": "Robert Beasley, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bossier City", 
                        "country": "United States", 
                        "state": "Louisiana", 
                        "zip": "71111"
                    }, 
                    "name": "Endovascular Technologies, LLC"
                }, 
                "investigator": {
                    "last_name": "William Eaves, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Plymouth", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55441"
                    }, 
                    "name": "Minneapolis Radiology and Vascular Research Foundation"
                }, 
                "investigator": {
                    "last_name": "Troy Long, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hattiesburg", 
                        "country": "United States", 
                        "state": "Mississippi", 
                        "zip": "39401"
                    }, 
                    "name": "Hattiesburg Clinic, PA"
                }, 
                "investigator": {
                    "last_name": "Robert Wilkins, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Flemington", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "08822"
                    }, 
                    "name": "Hunterdon Cardiovascular Associates"
                }, 
                "investigator": {
                    "last_name": "Andrey Espinoza, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toledo", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43614"
                    }, 
                    "name": "University of Toledo Medical Center"
                }, 
                "investigator": {
                    "last_name": "Mark Burket, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Prospective, Multicenter, Single-Blind, Randomized, Controlled Trial Comparing the Lutonix\u00ae Drug Coated Balloon vs. Standard Balloon Angioplasty for Treatment of Femoropopliteal In-Stent Restenosis", 
        "overall_contact": {
            "email": "Harrison.Malinoff@crbard.com", 
            "last_name": "Harrison Malinoff"
        }, 
        "overall_official": {
            "affiliation": "Yale University", 
            "last_name": "Carlos Mena, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Primary patency is defined as freedom from clinically driven TLR and from Binary Restenosis.", 
                "measure": "Efficacy: Primary Patency", 
                "safety_issue": "No", 
                "time_frame": "12 Months"
            }, 
            {
                "measure": "Safety: Freedom from all cause perioperative death, index limb amputation, index limb reintervention and index limb related death.", 
                "safety_issue": "Yes", 
                "time_frame": "30 Days and 1 year"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02063672"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Primary and Secondary Patency (DUS PSVR <2.5)", 
                "safety_issue": "Yes", 
                "time_frame": "6, 12 and 24 months"
            }, 
            {
                "measure": "Target Lesion Revascularization (TLR)", 
                "safety_issue": "Yes", 
                "time_frame": "6, 12 and 24 months"
            }, 
            {
                "measure": "Change of Rutherford classification from baseline", 
                "safety_issue": "Yes", 
                "time_frame": "6, 12 and 24 months"
            }, 
            {
                "measure": "Change of resting Ankle Brachial Index (ABI) from baseline", 
                "safety_issue": "Yes", 
                "time_frame": "6, 12 and 24 months"
            }, 
            {
                "measure": "Change in Walking Impairment Questionnaire from baseline", 
                "safety_issue": "Yes", 
                "time_frame": "6, 12 and 24 months"
            }, 
            {
                "measure": "Change in quality of life from baseline, as measured by EQ-5D", 
                "safety_issue": "Yes", 
                "time_frame": "6, 12 and 24 months"
            }, 
            {
                "measure": "Major vascular complications (\u226430 day)", 
                "safety_issue": "Yes", 
                "time_frame": "6, 12 and 24 months"
            }
        ], 
        "source": "C. R. Bard", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "C. R. Bard", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}